Our results suggest that fulvestrant is an effective drug that inhibits the pathogenic/carcinogenic effects of estrogen dependent IGF-1R, IRS-1, ER-α and PDZK1 signaling pathways to control breast cancer progression. This evidence concerns the gene IGF1R and breast carcinoma.